Content area


Behandling af svær aktiv morbus Crohn med adalimumab

Reservelæge Ulrich Christian Bang & overlæge Anette Mertz Nielsen Hvidovre Hospital, Gastroenheden
Ugeskr Læger 2008;170(25):2256
Blad nummer: 
Summary The use of adalimumab in severe fistulising Crohn's disease - three cases Ugeskr Læger 2008;170(25):2256 So far infliximab is the only approved anti-TNF-α antibody for patients with Crohn's disease. Development of antibodies to infliximab may result in allergic reactions or reduced effect. We report three patients who received adalimumab, which induced longstanding remission in all three patients.
Du skal være logget ind for at læse denne artikel
Log ind

Right side